Company Profile
DURECT Corporation Stock Price, News & Analysis
- Ticker:
- DRRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for DRRX.
Company overview
Business overview
DURECT was a specialty pharmaceutical company focused on pain, liver disease, and drug-delivery programs before its restructuring and public-market decline. Its story centered on trying to commercialize niche assets.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, DURECT sat in specialty biopharma.
Business Model Characteristics
The business depended on product development, delivery technology, and the chance to create value from a narrow portfolio.
Position Within the Biotechnology Landscape
DURECT belongs to the historical specialty-pharma set rather than the current live public-company universe.
Future catalysts
DURECT’s catalysts are legacy and transaction-related, with any remaining asset-resolution or capital-update milestone doing the work. The company is no longer a live pipeline name.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does DURECT Corporation do?
DURECT was a specialty pharmaceutical company focused on pain, liver disease, and drug-delivery programs before its restructuring and public-market decline. Its story centered on trying to commercialize niche assets.
On which exchange is DRRX stock listed?
DURECT Corporation (DRRX) is associated with NASDAQ, United States, Biopharma.
What future catalysts are investors watching for DURECT Corporation?
DURECT’s catalysts are legacy and transaction-related, with any remaining asset-resolution or capital-update milestone doing the work. The company is no longer a live pipeline name.